Myokardia (MYOK) Earning Somewhat Favorable Press Coverage, Accern Reports
Media stories about Myokardia (NASDAQ:MYOK) have been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Myokardia earned a news impact score of 0.11 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 42.6772306938692 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news stories that may have effected Accern Sentiment’s rankings:
- Myokardia Inc (MYOK) Receives Consensus Rating of “Hold” from Analysts (americanbankingnews.com)
- Zacks: Analysts Expect Myokardia Inc (MYOK) Will Post Quarterly Sales of $5.63 Million (americanbankingnews.com)
- Myokardia Inc (MYOK) Insider Sells $125,100.00 in Stock (americanbankingnews.com)
- Myokardia Inc (MYOK) Director Kevin P. Starr Sells 816,326 Shares (americanbankingnews.com)
- Brokerages Anticipate Myokardia Inc (MYOK) to Post -$0.40 Earnings Per Share (americanbankingnews.com)
A number of brokerages have issued reports on MYOK. Zacks Investment Research raised shares of Myokardia from a “sell” rating to a “hold” rating in a report on Tuesday, October 17th. JPMorgan Chase & Co. began coverage on shares of Myokardia in a report on Tuesday, December 12th. They issued an “overweight” rating and a $54.00 price target on the stock. BidaskClub raised shares of Myokardia from a “sell” rating to a “hold” rating in a report on Tuesday, December 26th. TheStreet lowered shares of Myokardia from a “c” rating to a “d+” rating in a report on Friday, November 3rd. Finally, Wedbush reissued an “outperform” rating and issued a $51.00 price target on shares of Myokardia in a report on Wednesday, September 20th. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. Myokardia presently has an average rating of “Hold” and a consensus target price of $54.83.
Shares of Myokardia (NASDAQ:MYOK) opened at $47.55 on Wednesday. The firm has a market cap of $1,700.00 and a PE ratio of -64.26. Myokardia has a 52 week low of $10.55 and a 52 week high of $49.55.
Myokardia (NASDAQ:MYOK) last announced its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.42) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.42). The firm had revenue of $5.63 million for the quarter, compared to analyst estimates of $6.10 million. Myokardia had a negative net margin of 53.49% and a negative return on equity of 14.92%. The company’s revenue for the quarter was up 58.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.35) EPS. equities analysts predict that Myokardia will post -1.62 earnings per share for the current year.
In related news, CEO Anastasios Gianakakos sold 4,300 shares of Myokardia stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $40.23, for a total transaction of $172,989.00. Following the completion of the transaction, the chief executive officer now directly owns 513,417 shares of the company’s stock, valued at approximately $20,654,765.91. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Kevin P. Starr sold 816,326 shares of Myokardia stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $42.00, for a total transaction of $34,285,692.00. The disclosure for this sale can be found here. Insiders have sold a total of 831,626 shares of company stock worth $34,921,501 in the last ninety days. Insiders own 33.40% of the company’s stock.
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.